NICE approves secukinumab for chronic pain condition
NICE has recommended the use of secukinumab as an option for treating a chronic back pain condition affecting young adults.
Novartis, which markets secukinumab 150mg injectable solution as Cosentyx, announced yesterday (June 17) that NICE had approved the medicine for adults with non-radiographic axial spondyloarthritis (nr-axSpA) that is not controlled sufficiently by NSAIDs.
The inflammatory back pain condition, which can cause severe discomfort and in some cases irreversible spine damage, is thought to affect around 165,000 people in the UK, with symptoms typically developing around the age of 24. However, Novartis claims nr-axSpA is widely underdiagnosed, with UK patients waiting an average of 8.5 years before they receive a diagnosis.
The NICE recommendation is based on data from the Phase III PREVENT study, described as the largest ever study involving the use of a biologic in patients with nr-axSpA. The study showed a “significant reduction” in disease activity at week 16 compared to placebo.
Previous clinical studies have shown that secukinumab can be used to help manage psoriasis, psoriatic arthritis and ankylosing spondylitis.
“The decision from NICE in nr-axSpA follows recent Scottish Medicines Consortium (SMC) approval and means secukinumab is now recommended as a much-needed additional treatment option for people with this debilitating condition in England, Scotland and Wales,” said Novartis UK’s Caitriona Walsh.
Dr Raj Sengupta, consultant rheumatologist at the Royal National Hospital for Rheumatic Diseases commented: “nr-axSpA can take a huge toll on patients’ physical and mental health at a young age with symptoms including chronic pain, morning stiffness, fatigue and reduced mobility, making everyday tasks a real challenge.
“If left untreated, nr-axSpA may cause irreversible damage, subjecting people to a lifetime of intense back pain. The NICE decision is a key milestone for clinicians and patients who will now have access to an additional treatment option that may help patients.”
Learn how to help customers with constipation and find out how even brief conversations can have a positive influence on their health.
Understand how fungal nail infections develop and help manage customer expectations around treatment
Record my learning outcomes
Inspiring stories related to health, fitness and the pursuit of wellbeing
More like this
Royal Family hails pharmacy teams in Covid-19 fight
The Royal Family last night paid tribute to pharmacists and their teams in the fight against coronavirus.
1 Min Article
Well says one million sign up to text message service
Well claims one million patients have signed up to its prescription medicine text messaging service.Â
1 Min Article
More money for GPs as 2021/22 contract details revealed
Funding increases for GP practices and PCNs have been agreed as details of the GP contract for 2021-22 were unveiled last week.
1 Min Article
Relief from the nasal symptoms of allergy
With NHS England advising that OTC products should no longer be prescribed to treat mild-to-moderate hayfever, pharmacy’s role in supporting sufferers is more important than ever. This module includes self-care advice and product recommendations to aid customer conversations.
5 Min Module